Press Releases TaiMed Biologics Inc.

Equities

4147

TW0004147004

End-of-day quote Taipei Exchange Other stock markets 23:00:00 07/05/2024 BST			5-day change	1st Jan Change
86.7 ^TWD	0.00%		+1.40%	+5.73%

03-20	TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
03-13	Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TaiMed Biologics : First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy	28/07/22	PU
TaiMed Biologics : Important Resolutions of the Company's 2022 General Shareholders' Meeting	30/05/22	PU
TaiMed Biologics : Announcement of members of the Company's Compensation Committee	30/05/22	PU
TaiMed Biologics : Announcement of members of the Company's 3rd Audit Committee	30/05/22	PU
TaiMed Biologics : 2022 general shareholders' meeting approved the lifting of non-competition restrictions for directors	30/05/22	PU
TaiMed Biologics : Announcement of the Company's list of newly elected directors and independent directors	30/05/22	PU
TaiMed Biologics : Announcement of Change of Board of Directors Chairperson	30/05/22	PU
TaiMed Biologics : received the official approval letter from US FDA for the pre-approval inspection (PAI) of cGMP monoclonal antibody facility	26/05/22	PU
TaiMed Biologics : Enrollment of Phase III Clinical Study Is Complete for Trogarzo Intramuscular Injection (IM)	27/04/22	PU
TaiMed Biologics : Receives from Theratechnologies Notification of Returning Commercialization Rights for Trogarzo in European Territory	27/04/22	PU
TaiMed Biologics : The US FDA completed a pre-approval inspection (PAI) of TaiMed cGMP monoclonal antibody facility with no observation	20/04/22	PU
TaiMed Biologics : EMA Approves Supplemental BLA Filing for The Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo	13/04/22	PU
TaiMed Biologics : Announcement of Change of the Company's CEO (President/General Manager)	11/04/22	PU
TaiMed Biologics : The US FDA Approves IND Applicaion for Bi-monthly and Quarterly dosing of TMB-365/TMB-380 Combination for Treatment of HIV Infection	01/04/22	PU
TaiMed Biologics : The Company's 2021 consolidated financial statements have been approved by the Board of Directors	11/03/22	PU
TaiMed Biologics : The Company's Board of Directors resolved to convene the 2022 Annual Shareholders' Meeting	11/03/22	PU
TaiMed Biologics : The Company's Board of Directors resolved not to distribute dividends	11/03/22	PU
TaiMed Biologics : Exxpands Its Business Model from Biologic Drug Innovator to Contract Development and Manufacturing Organization (CDMO).	11/03/22	PU
TaiMed Biologics : Submission of IND Applicaion with the US FDA for Bi-monthly and Quarterly dosing of TMB-365/TMB-380 Combination for Treatment of HIV Infection	03/03/22	PU
TaiMed Biologics : The US FDA Approves Supplemental BLA Filing for The Addition of Samsung Biologics in Korea for Commercial Manufacturing of Trogarzo	23/02/22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases TaiMed Biologics Inc.

Equities

4147

TW0004147004

Press Releases

Filters